NCT04472598 2026-03-23
TRANSFORM-1
AbbVie
Phase 3 Completed
Clinical Trials
8 trialsNCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT05663827 2024-03-05
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
Chang Gung Memorial Hospital
Phase 3 Completed
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT02292446 2019-07-18
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT00952289 2018-03-12
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Incyte Corporation
Phase 3 Completed
NCT01632904 2017-11-14
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
Incyte Corporation
Phase 3 Completed